Scale -


  • Revenue is 770 Rs Cr; Annual Growth is 19 %; Continuous Growth over 3 years
  • Ebitda is 160 Rs Cr; Annual Growth is 89 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 23 %
  • PBT is 30.04 Rs Cr; Annual Growth is 87 %; 5 Year CAGR is 39 %
  • PAT is 103 Rs Cr; Annual Growth is 127 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 26 %

Profitability -


  • PBDIT Margin is 20.77 %; Annual Growth is 59 %; Continuous Growth over 3 years; 5 Year CAGR is 15 %
  • PAT Margin is 13.35 %; Annual Growth is 91 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 18 %

Return -


  • ROCE is 19.39 %; Annual Growth is 81 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 27 %
  • ROA is 12.04 %; Annual Growth is 90 %; Continuous Growth over 3 years; in Top Quartile
  • ROE is 15.48 %; Annual Growth is 92 %; Continuous Growth over 3 years; in Top Quartile
  • Asset Turnover is 98 %; in Top Quartile

Efficiency -


  • Operating cash flow is 156 Rs Cr; Annual Growth is 80 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 40 %
  • Inventory Turnover Ratio is 6.7; Continuous Growth over 3 years; 5 Year CAGR is 22 %
  • Quick Ratio is 1.64; Annual Decline is -36 %; Continuous Decline over 3 years
  • Current Ratio is 2.44; Continuous Decline over 3 years

Solvancy -


  • Total Debt is 0 Rs Cr; Annual Decline is -100 %; Continuous Decline over 3 years; in Bottom Quartile
  • Debt/Equity is 0; in Bottom Quartile
  • Contingent Liabilities is 46.62 Rs Cr; in Top Quartile; 5 Year CAGR is 44 %

Quality -


  • Exceptional Items/PBT is 0 %; Annual Decline is -100 %; in Top Quartile
  • Current Tax/PAT is 32 %; Annual Decline is -23 %
  • Change in Inventories/Total Expenses is -2 %; Annual Decline is -323 %
  • Operating cashflow/ebitda is 97 %; in Top Quartile
  • Operating cashflow/PAT is 152 %; in Top Quartile; Annual Decline is -21 %

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Venus Remedies (NSE:VENUSREM) Q2 FY27 Board Outcome and European Units
Venus Remedies Q2 EBITDA margin expands to 19.43% on revenue growth
Venus Remedies Q2 FY27 Results: Key Financials Disclosed
Venus Remedies Q2 Results FY27: Profit Up 27.42% to Rs 25.65 Cr
Below All Moving Averages and Now at Lower Circuit: Venus Remedies Ltd Loses 4.9% in a Single Session
Venus Remedies International Drug Approvals and Market Expansion
Venus Remedies receives five marketing approvals In Kazakhstan, Peru, Kuwait, Argentina
Is Venus Remedies the Best Stock in Its Sector? A Look at the Numbers
Venus Remedies (NSE:VENUSREM) Secures Five Global Drug Approvals
Venus Remedies secures 5 marketing authorisations in 4 global markets
Venus Remedies Upper Circuit Today: Price, Data and Peers
Venus Remedies VENUSREM Q2 FY27 Regulation 74(5) Compliance